Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects

Journal of Nuclear Medicine

Volumn 40, Issue 2, 1999, Pages 283-289

  Chan, Grace Lap Yu ^a   Holden, James E ^b   Stoessl, A Jon ^b   Samii, Ali ^b   Doudet, Doris J ^b   Dobko, Teresa ^b   Morrison, K Scott ^b   Adam, Michael ^b   Schulzer, Michael ^b   Calne, Donald B ^b   Ruth, Thomas J ^b  

^a VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

11C dihydrotetrabenazine; PET imaging; Vesicular monoamine transporter 2

Indexed keywords

BRAIN MONOAMINE; CARBON 11; CARRIER PROTEIN; DIHYDROTETRABENAZINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CARBON; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MEMBRANE PROTEIN; NEUROPEPTIDE; RADIOPHARMACEUTICAL AGENT; TETRABENAZINE; VESICULAR AMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER;

ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; CEREBELLUM; FEMALE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; MEMBRANE VESICLE; MONOAMINE RELEASE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DETERMINATION; TISSUE DISTRIBUTION; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; OCCIPITAL LOBE; REPRODUCIBILITY; SCINTISCANNING;

ADULT; AGED; BRAIN; CARBON RADIOISOTOPES; CEREBELLUM; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; OCCIPITAL LOBE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TETRABENAZINE; TOMOGRAPHY, EMISSION-COMPUTED; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0032588607     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pletscher A, Brossi A, Grey KF. Benzoquinoline derivatives: a new class of monoamine decreasing drugs with psychotropic action. Int Rev Neurobiol. 1962;4:275-306.
2. Henry JP, Scherman D. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochemical Pharmacol. 1989;38:2395-2404.
3. Vander Borght TM, Kilbourn MR, Koeppe RA, et al. In vivo imaging of the brain vesicular monoamine transporter. J Nucl Med. 1995;36:2252-2260.
4. Masuo Y, Pelaprat D, Scherman D, Rostene W. 3-H-dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum. Neurosci lett. 1990;114:45-50.
5. 3H]Dihydrotetrabenazine binding to bovine striatal synaptic vesicles. Mol Pharmacol. 1986;30:252-257.
6. Lehericy S, Brandel JP, Hirsch EC, et al. Monoamine vesicular uptake sites in patients with Parkimon's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. Brain Res. 1994;659:1-9.
7. Thibaut F, Faucheux BA, Marquez J, et al. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. Brain Res. 1995;692:233-243.
8. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol. 1995;294:577-583.
9. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci. 1996;16:3507-3510.
10. 11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab. 1996;16:1288-1299.
11. Koeppe RA, Frey KA, Vander Borght TM. et al. Kinetic evaluation of alpha-[C-11]dihydrotetrabenazine (DTBZ): a PET ligand for assessing the vesicular monoamine transporter [abstract]. J Nucl Med. 1995;36:118P.
12. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol. 1993;40:873-884.
13. Gilman S, Frey KA, Koeppe RA, et al. Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography. Ann Neurol. 1996;40:885-892.
14. Kilbourn MR, Lee LC, Vander Borght TM, Jewett DM, Frey KA. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol. 1995;278:249-252.
15. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
16. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
17. Scheffe H. The Analysis of Variance. New York, NY: Wiley & Sons; 1959:221-260.
18. Fleiss JL. The Design and Analysis of Clinical Experiments. New York, NY: Wiley & Sons; 1986.
19. Kish SJ, Robaitaille Y, El-Awar M, et al. Striatal monoamine neurotransmitters and metabolites in dominantly inherited olivopontocerebellar atropy. Neurology. 1992;42:1573-1577.
20. Logan J, Volkow ND, Fowler JS, et al. Effects of blood flow on [11-C]raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab. 1995;14:995-1010.
21. 1 receptor tracer, in normal subjects. J Nucl Med. 1998;39:792-797.